BioNxt Announces Enhanced Sublingual Product Development Pipeline with Innovative Solutions for Autoimmune Diseases and Longevity
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) announces expansion of its next-generation product pipeline, focusing on proprietary drug delivery systems for autoimmune diseases and longevity markets. The pipeline includes BNT23001 for Multiple Sclerosis using sublingual Cladribine formulation, targeting a market projected to exceed $41B by 2033. Additional developments include treatments for Myasthenia gravis ($6.7B market by 2032), Lupus nephritis ($3.2B by 2032), Rheumatoid arthritis ($27B by 2033), and anti-aging solutions for the longevity sector ($93B by 2027).
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) annuncia l'espansione della sua pipeline di prodotti di nuova generazione, concentrandosi su sistemi di somministrazione di farmaci proprietari per malattie autoimmuni e mercati della longevità. La pipeline include BNT23001 per la sclerosi multipla utilizzando una formulazione sublinguale di Cladribina, mirando a un mercato previsto superiore ai 41 miliardi di dollari entro il 2033. Sviluppi aggiuntivi includono trattamenti per miastenia grave (mercato di 6,7 miliardi di dollari entro il 2032), nefrite lupica (3,2 miliardi entro il 2032), artrite reumatoide (27 miliardi entro il 2033) e soluzioni anti-invecchiamento per il settore della longevità (93 miliardi entro il 2027).
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) anuncia la expansión de su pipeline de productos de nueva generación, enfocándose en sistemas de entrega de medicamentos propietarios para enfermedades autoinmunes y mercados de longevidad. El pipeline incluye BNT23001 para esclerosis múltiple utilizando una formulación sublingual de cladribina, dirigiéndose a un mercado que se proyecta que superará los 41 mil millones de dólares para 2033. Los desarrollos adicionales incluyen tratamientos para miastenia gravis (mercado de 6.7 mil millones para 2032), nefitis lúpica (3.2 mil millones para 2032), artritis reumatoide (27 mil millones para 2033) y soluciones antienvejecimiento para el sector de la longevidad (93 mil millones para 2027).
BioNxt Solutions (CSE:BNXT, OTC:BNXTF)는 자가면역 질환과 장수 시장을 위한 독점 약물 전달 시스템에 중점을 두고 차세대 제품 파이프라인을 확장한다고 발표했습니다. 파이프라인에는 다발성 경화증에 대한 BNT23001이 포함되어 있으며, 클라드리빈 서브링구알 제형을 사용하여 2033년까지 410억 달러를 초과할 것으로 예상되는 시장을 타겟팅합니다. 추가 개발에는 중증 근무력증 (2032년까지 67억 달러 시장), 루푸스 신염 (2032년까지 32억 달러), 류마티스 관절염 (2033년까지 270억 달러) 및 장수 부문을 위한 노화 방지 솔루션이 포함됩니다 (2027년까지 930억 달러 시장).
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) annonce l'expansion de son portefeuille de produits de nouvelle génération, en se concentrant sur des systèmes de délivrance de médicaments propriétaires pour les maladies auto-immunes et les marchés de la longévité. Le portefeuille comprend BNT23001 pour la sclérose en plaques utilisant une formulation sublinguale de cladribine, visant un marché qui devrait dépasser 41 milliards de dollars d'ici 2033. Les développements supplémentaires incluent des traitements pour la myasthénie grave (marché de 6,7 milliards de dollars d'ici 2032), la néphrite lupique (3,2 milliards d'ici 2032), l'arthrite rhumatoïde (27 milliards d'ici 2033) et des solutions anti-vieillissement pour le secteur de la longévité (93 milliards d'ici 2027).
BioNxt Solutions (CSE:BNXT, OTC:BNXTF) kündigt die Expansion seines Produktportfolios der nächsten Generation an und konzentriert sich auf proprietäre Arzneimittelabgabesysteme für Autoimmunerkrankungen und den Bereich Langlebigkeit. Das Portfolio umfasst BNT23001 für Multiple Sklerose mit einer sublingualen Cladribin-Formulierung, die auf einen Markt abzielt, der bis 2033 voraussichtlich über 41 Milliarden Dollar übersteigen wird. Weitere Entwicklungen umfassen Behandlungen für Myasthenia gravis (6,7 Milliarden Dollar Markt bis 2032), Lupusnephritis (3,2 Milliarden bis 2032), Rheumatoide Arthritis (27 Milliarden bis 2033) und Anti-Aging-Lösungen für den Bereich Langlebigkeit (93 Milliarden bis 2027).
- Targeting multiple high-value markets with combined potential exceeding $171B
- Lead product BNT23001 addresses MS market where current Cladribine tablets achieved $1B+ sales in 2023
- Innovative drug delivery systems potentially improving patient compliance and drug bioavailability
- Early-stage development with no immediate revenue generation
- Multiple competitors in established markets
VANCOUVER, BC / ACCESSWIRE / November 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to announce the expansion of its next-generation product pipeline. This includes proprietary Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet) drug delivery systems targeting autoimmune diseases such as Multiple sclerosis ("MS"), Myasthenia gravis ("MG"), Lupus nephritis ("LN"), and Rheumatoid arthritis ("RA"), as well as an exciting initiative in the fast-growing longevity market. These advancements highlight BioNxt's commitment to developing innovative, patient-centric solutions to improve compliance, enhance drug bioavailability, and address critical unmet medical needs.
Pipeline Highlights
1. BioNxt Lead Product BNT23001: Multiple sclerosis (MS)
BioNxt's lead pipeline product for MS is a proprietary sublingual (thin-film) formulation of Cladribine, offering an innovative alternative to traditional oral tablets. This next-generation delivery system is designed to overcome the challenges of swallowing difficulty, a common issue among MS patients, while enhancing drug absorption and compliance.
Cladribine tablets are currently approved in over 75 countries and achieved sales exceeding USD 1 billion in 2023 (Merck KGaA). With the global MS drug market projected to exceed USD 41 billion by 2033 (Market.us), BioNxt's sublingual (thin-film) product offers a unique, patient-friendly approach.
2. BioNxt BNT23001: Myasthenia gravis (MG)
Building on its MS expertise, BioNxt is repurposing its sublingual (thin-film) Cladribine technology for Myasthenia gravis, a chronic neuromuscular condition that causes muscle weakness and fatigue. Patients with MG often face difficulty swallowing, making BioNxt's sublingual delivery system an ideal solution. The global MG market is anticipated to reach USD 6.7 billion by 2032 (Clinical Trials Arena).
3. BioNxt BNT24002: Lupus nephritis (LN)
BioNxt is developing a proprietary sublingual (thin-film) product for Lupus nephritis, a serious autoimmune condition that can lead to kidney failure. This innovative drug delivery system focuses on maximizing bioavailability while minimizing side effects, addressing a critical gap in the LN treatment market, which is expected to grow to USD 3.2 billion by 2032.
4. BioNxt BNT24003: Rheumatoid arthritis (RA)
Rheumatoid arthritis is a prevalent autoimmune condition affecting millions globally, causing joint pain, swelling, and reduced mobility. BioNxt is leveraging its expertise in sublingual (thin-film) and oral (enteric-coated tablet) technologies to develop proprietary solutions that improve compliance and therapeutic outcomes. The global RA drug market is projected to surpass USD 27 billion by 2033 (Precedence Research).
5. BioNxt BNT24004: Formulation for Longevity and Anti-Aging
BioNxt is also entering the booming longevity and anti-aging sector, projected to reach USD 93 billion by 2027 (Statista). The Company is advancing proprietary sublingual (thin-film) and oral (enteric-coated tablet) drug products with active pharmaceutical ingredients that show early-stage evidence of benefits such as slowing ovarian aging, extending fertility, and promoting healthy aging. These innovative solutions are tailored to meet the growing demand for effective anti-aging therapies.
BioNxt Drug Delivery System: Advancing Health with Precision Medicine
BioNxt's proprietary drug delivery system-sublingual (thin-film), transdermal (skin patch), and oral (enteric-coated tablet)-represent a significant step forward in improving therapeutic outcomes. By focusing on next-generation technologies, BioNxt is delivering patient-friendly solutions that prioritize convenience, precision, and bioavailability across a range of major high-growth therapeutic markets.
"Our expanded pipeline showcases BioNxt's leadership in next-generation drug delivery," said Hugh Rogers, CEO of BioNxt Solutions. "With innovative solutions like sublingual (thin-film), transdermal (skin patch), and oral (enteric-coated tablet) systems, we're addressing unmet needs in critical markets, improving patient outcomes, and driving long-term growth opportunities for BioNxt."
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablet)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity. With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, initially focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT; OTC Markets: BNXTF; and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
BioNxt Solutions Inc.
Hugh Rogers, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
FAQ
What are the main markets targeted by BioNxt (BNXTF) in their latest pipeline announcement?
What is the market size projection for BioNxt's (BNXTF) Multiple Sclerosis treatment market?
What is BioNxt's (BNXTF) lead product BNT23001?
